Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to evaluate effectiveness and safety of ChiCGB
regimen( chidamide, cladribine, gemcitabine and busulfan).
Busulfan are designed to kill cancer cells by binding to DNA (the genetic material of cells),
which may cause cancer cells to die.
Gemcitabine and cladribine are designed to disrupt the growth of cancer cells, which may
cause cancer cells to die. It may help to increase the effect of busulfan on cancer cells by
not allowing these cells to repair the DNA damage caused by busulfan.
Chidamide is designed to open up the DNA and allow greater access to drugs that bind to DNA,
such as cladribine, gemcitabine, busulfan.